A phase 2 trial of NSHO-101 [EA1080] in patients with ulcerative colitis
Latest Information Update: 28 Jun 2024
At a glance
- Drugs EA 1080 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
Most Recent Events
- 28 Jun 2024 New trial record
- 27 Jun 2024 According to an Ensho Therapeutics media release, the company plans to initiate Phase 2 clinical development in the first half of 2025.